#62025CC0354EU Advocate General opinion on language labels for parallel-imported medicines
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This opinion addresses when parallel-imported medicines must carry labels in the official language of the country where they are sold, even if relabelling would damage the product’s immediate packaging. The issue matters for pharmaceutical importers, regulators, pharmacies, and patients. If the Court follows the opinion, it may clarify how far national language rules can go when they collide with the free movement of medicines and the need to keep products available without compromising patient safety.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Examines whether national language labelling rules still apply when relabelling a parallel-imported medicine would damage its immediate packaging
- Focuses on the balance between free movement of medicinal products and patient safety
- Highlights the possible use of exemptions under EU medicines law when availability problems or non-direct patient delivery are involved
Obligations
What this law requires
Article 63(1) of Directive 2001/83 requires medicinal product labelling particulars listed in Articles 54, 59 and 62 to appear in the official language or languages of the Member State where the product is placed on the market, as specified by that Member State.
Article 63(3) of Directive 2001/83 permits competent authorities to grant full or partial exemptions from national language requirements for labelling and package leaflets where the medicinal product is not intended to be delivered directly to the patient or where severe availability problems exist, subject to measures necessary to safeguard human health.
The challenged German measure requires finished medicinal products placed on the German market to carry mandatory particulars in German on containers and, where applicable, outer packaging; this requirement is at issue and should not be treated as a settled EU compliance obligation in this opinion.
The Advocate General opinion concerns whether national language labelling rules may still apply when a parallel importer cannot relabel a medicinal product without damaging its immediate packaging, balancing patient safety against free movement of goods under Article 34 TFEU.